Mintz Levin Represents QIAGEN N.V. in Public Offering
12/1/2009
Boston, MA - Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented QIAGEN N.V., the leading provider of sample and assay technologies, in the company's global offering of common stock, which raised more than $640 million in gross proceeds.
Serving as U.S. counsel to Netherlands-based QIAGEN N.V., Mintz Levin attorneys involved in the transaction included: Jonathan Kravetz, Chair of the firm's Securities Practice, Sahir Surmeli, a member in the firm's Corporate and Life Science Practices, Daniel Follansbee, a member in the Corporate Practice as well as Corporate Practice associates Ann Margaret Eames and Kevin Fay.
With one of the largest life sciences practices in the United States, Mintz Levin has represented more than 400 life sciences clients since the industry's inception in the 1970s and has been described by Chambers as "a leading life sciences brand." In the past five years alone, the firm's Life Sciences Practice has completed more than 340 transactions including: mergers and acquisitions totaling over $7 billion; venture capital deals totaling over $1.1 billion; more than 50 public offerings totaling over $5.2 billion; numerous strategic collaborations valued at over $2.5 billion and dozens of other financings.
